A Comparison of 2 Paclitaxel-Coated Balloon Systems in Treatment of De Novo Coronary Artery Lesions
View abstract on PubMed
Summary
This summary is machine-generated.Two paclitaxel drug-coated balloon systems showed similar safety and efficacy for treating de novo coronary lesions in a real-world study. Both systems may be suitable treatment options for patients with coronary artery disease.
Area Of Science
- Cardiology
- Interventional Cardiology
- Medical Devices
Background
- Drug-coated balloons (DCB) show promise for percutaneous coronary intervention (PCI) in small vessel disease.
- Real-world evidence for DCB in de novo coronary lesions is limited.
- Paclitaxel-coated balloons are a key therapeutic option for coronary artery disease.
Purpose Of The Study
- To compare the 12-month clinical outcomes of two paclitaxel-coated balloon systems.
- Evaluate the efficacy and safety of SeQuent Please and In.Pact Falcon DCB.
- Assess real-world performance in treating de novo coronary artery lesions.
Main Methods
- Retrospective study of 496 patients treated with SeQuent Please or In.Pact Falcon DCB.
- Inclusion criteria: de novo coronary artery stenosis treated from January 2014 to December 2018.
- Primary endpoint: 12-month composite of cardiac death, nonfatal myocardial infarction, and target vessel revascularization (3-point MACE).
Main Results
- No significant difference in 12-month 3-point MACE between SeQuent Please (4.2%) and In.Pact Falcon (2.3%) (P=.272).
- Cardiovascular death rates were low and similar between groups (2.7% vs 1.1%; P=.20).
- Baseline characteristics were comparable across both treatment groups.
Conclusions
- Both paclitaxel DCB systems demonstrate similar efficacy and safety profiles.
- These findings suggest both devices may be appropriate for treating de novo coronary lesions.
- Further randomized controlled trials are warranted to confirm these results.

